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Abstract 
Study Design. Fusion success with rhBMP-2 and autograft in titanium or PEEK corpectomy devices was 
evaluated in a sheep lumbar corpectomy model. The 6 treatment groups included titanium mesh or 
PEEK corpectomy devices filled with rhBMP-2 on a compression-resistant matrix (CRM) carrier; rhBMP-2 
in a morselized absorbable collagen sponge (ACS) carrier combined with resorbable ceramic granules; 
and autograft. 
Objective. The aim of this study was to determine fusion rates associated with 2 different preparations 
of rhBMP-2 as well as autograft in an instrumented ovine lumbar corpectomy model 6 months 
postoperatively. 
Summary of Background Data. Vertebral reconstruction with corpectomy devices requires bone graft. 
Bone graft substitutes have the potential to avoid a second operation, donor site pain, and attendant 
morbidity associated with autograft. 
Methods. Twenty-four sheep in 6 treatment groups underwent lumbar corpectomy via a 
retroperitoneal trans-psoas approach. Spines were reconstructed with autograft, rhBMP-2 on a CRM, or 
rhBMP-2 on an ACS mixed with ceramic granules. Grafting materials were placed in either a titanium 
mesh or PEEK conduit in spines with internal fixation. Computed tomographic (CT) scans were evaluated 
for fusion. Undecalcified histology was used to evaluate for fusion as well as the amount and extent of 
graft incorporation and graft resorption. 
Results. Regardless of corpectomy device used, rhBMP-2/CRM or rhBMP-2/ACS with MASTERGRAFT 
resulted in a 100% fusion rate. The autograft group had a lower (75%) radiographic fusion rate. Using 
either preparation of rhBMP-2 resulted in the length of the defect filling with solid bone. Autograft 
fragments and ceramic granules were incorporated into the fusion masses with much of the ceramic 
granules being resorbed by 6 months. 
Conclusion. Both of the rhBMP-2 formulations have the potential to effect bony fusion and vertebral 
reconstruction within the corpectomy devices. 
Key words: arthrodesis, autograft, bone morphogenetic protein 2, corpectomy, instrumented, lumbar 
spine fusion, PEEK, rhBMP-2, sheep model, titanium. 
 
Acorpectomy is a surgical procedure performed subsequent to a fracture, a tumor, infection, or 
degenerative spondylitic disease, which involves removing all or part of the vertebral body and 
intervertebral discs to provide neural decompression followed by surgical reconstruction of the 
corpectomy defect using a strut autograft, strut allograft, or a corpectomy device filled with 
autograft bone. Autograft bone, locally harvested from the vertebral body, the anterolateral spine, or 
harvested from the iliac crest, rib, or fibula is often considered the ‘‘gold standard’’ for achieving bony 
fusion following corpectomy and subsequent vertebral body reconstruction. Although bone autograft is 
more osteogenic that facilitates early graft healing and incorporation, harvesting of iliac crest, rib, or 
fibular autograft is known to be associated with donor site pain and donor site complications, including 
injury to nerves or blood vessels, hematoma formation, infection at the donor site, cosmetic deformity, 
abdominal hernia, and/or fracture at the donor site.1–9 
 In addition to bone autograft, a strut bone allograft from a donor femur, tibia, or humerus may 
be used to reconstruct the vertebral body after corpectomy. Similar to strut autograft, strut allograft 
provides a biomechanical advantage with early structural support provided by the intact cortical bone. 
The use of strut allograft for corpectomy has the added advantage of decreasing operative time, blood 
loss, and avoiding donor site pain and morbidity associated with autograft harvest. However, strut 
allograft lacks the osteogenic potential and ability to become fully incorporated in contrast to cancellous 
bone autograft. For this reason, strut allografts for corpectomy reconstruction can be filled with 
autograft bone or a bone graft substitute to enhance osteoconductive and osteoinductive qualities. 
Allograft bone also has additional concerns of pseudarthrosis and disease transmission due to 
insufficient or improper donor evaluation, contamination, recipient infection, and positive serologic 
tests.10 
 Often times, lack of volume of local bone or iliac crest volume to be used for reconstruction can 
become problematic. Bone morphogenetic proteins (BMPs) are a group of growth factors also known as 
cytokines that were discovered due to their ability to induce de novo bone and cartilage formation. 
Previous literature has shown that BMP-2 is a potent osteoinductive morphogen capable of inducing de 
novo bone formation in ectopic sites and stimulating bony healing and repair in orthotopic bony sites. 
The mechanism of action of rhBMP-2 involves the osteoinductive signaling and regulation of gene-
expression pathways involving the recruitment and differentiation of mesenchymal progenitor cells into 
osteoblasts resulting in bone formation at the implantation site.11,12 In 2002 and following U.S. Food and 
Drug Administration (FDA)-approved clinical studies, the combination of 1.5 mg/mL of rhBMP-2 on an 
absorbable collagen sponge (ACS) carrier (INFUSE Bone Graft, Medtronic Sofamor Danek, Memphis, TN) 
was approved as an autograft replacement in specific anterior lumbar interbody fusions (ALIFs).13–15 
Since its introduction in 2002, INFUSE Bone Graft has been used to induce spinal fusion, although clinical 
complications associated with the off-label use of rhBMP-2 have been reported in the literature.16,17 
 There is a paucity of literature on the use of rhBMP-2 for vertebral reconstruction subsequent to 
corpectomy. Using a bovine corpectomy model, White et al18 evaluated rhBMP-2 within strut allograft 
(N¼8) and local autograft within strut allograft (N¼8) for reconstruction of calf lumbar (L3) corpectomy 
defects at 4 months. Radiography and histology demonstrated comparable fusion (7/8 versus 8/8 for 
rhBMP-2) at the host allograft junction.18 The authors concluded: ‘‘Large cortical strut allografts (after 
lumbar corpectomy) supplemented with rhBMP-2 had incorporation and fusion strength comparable to 
allografts enhanced with cancellous autograft.’’18 
 In a clinical case series of 15 patients with vertebral instability and/or neurological compromise 
due to vertebral osteomyelitis, Aryan et al19 describe their experience in performing corpectomy and 
fusion with titanium cages filled with morselized allograft/autograft and rhBMP-2 in conjunction with 
tailored antibiotic therapy. Even though rhBMP-2 is contraindicated in patients with an active infection 
at the operative site, radiography demonstrated evidence of fusion in all patients at the last follow-up 
examination despite the underlying infections.19 In 2013, Pourtaheri et al20 described 5-year outcome 
results from 24 consecutive patients with cervical spondylosis who were treated with cervical 
corpectomy and a lower dose of rhBMP-2 (0.26–0.35 mg/level) mixed with local autograft and 
demineralized bone matrix (DBM) within a polyetheretherketone (PEEK) spacer with supplemental 
anterior instrumentation. The authors found that the 100% fusion rate at 6 months was maintained at a 
mean 5-year followup, with no cervical swelling, hematoma formation, or increase in length of stay.20 
 To our knowledge, there have been no studies to evaluate recombinant human BMP-2 (rhBMP-
2) as an alternative to autograft bone for reconstruction of a corpectomy. The purpose of this study was 
to evaluate 2 different formulations of rhBMP-2 in addition to autograft within 2 different corpectomy 
devices in an instrumented ovine lumbar corpectomy model. CT radiography and undecalcified histology 
were conducted in a blinded fashion to assess the efficacy of the 6 treatment groups to effect vertebral 
reconstruction following instrumented lumbar corpectomy at 6 months. 
MATERIALS AND METHODS 
Surgical Procedure 
A total of 24 skeletally mature (2–3 year old) female sheep were assigned to 1 of 6 treatment groups. All 
experimental procedures were approved by the Institutional Animal Care and Use Committee. Sheep 
were placed in right lateral recumbency and a left retroperitoneal transpsoas approach to the lumbar 
spine was made. A corpectomy of the L2 (intended) lumbar vertebral body was performed followed by 
preparation of the remaining endplates for arthrodesis. Once the vertebral body and intervertebral discs 
were excised, the staples were placed on the vertebral bodies above and below the vertebrectomy level 
and the awl was passed through the staple followed by tapping of the awl holes. Next, screws were 
placed through the staple to secure it to the vertebral body. After a measuring caliper was used to 
determine the required device length, the PEEK or titanium corpectomy device filled with the bone graft 
or bone graft substitute was inserted into the prepared space between the endplates as shown in Figure 
1A and B. As seen in Figure 1C, the spinal construct also included supplemental instrumentation (CD 
HORIZON ANTARES Spinal System; Medtronic, Memphis, TN) consisting of 4 screws with 2 rods and 
crosslink plates, and vertebral body staples. Animals received 15mg fentanyl patches for 3 postoperative 
days for pain control as well as a postoperative antibiotic and were individually housed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A) PEEK corpectomy device implanted into a 
corpectomy 
defect in the sheep lumbar spine. (B) Pyramesh device 
implanted 
into a corpectomy defect in a sheep spine. (C) PEEK 
corpectomy 
device implanted into a corpectomy defect with supplemental 
instrumentation 
(CD HORIZON ANTARES Spinal System; Medtronic 
Spinal and Biologics, Memphis, TN). 
 
Graft Materials and Treatment Groups 
Corpectomy Devices 
A PEEK vertebral body replacement implant (VERTESTACK 
CORNERSTONE PSR PEEK Implant; Medtronic) 
was used to reconstruct the vertebral body and used with supplemental fixation. The PEEK device was 
modular with the central portion of the device measuring 14mm_11mm_25mm.To this central portion, 
additional modules were placed at each end so that the PEEK construct matched the size of the created 
corpectomy defect. Titanium surgical mesh devices (PyrameshC Titanium Mesh Implant; Medtronic, 
Memphis, TN) were also used. These devices were 13mm in diameter. 
Bone Graft and Bone Graft Substitutes 
Sheep were assigned to 1 of 6 treatment groups as summarized in Table 1. Three of the groups included 
the titanium mesh devices filled with rhBMP-2 on a CRM [rhBMP-2/CRM], rhBMP-2 on ACS mixed with 
biphasic HA/TCP (15% Hydroxyapatite/85%b-Tricalcium Phosphate) ceramic granules [rhBMP-2/ACS 
with MASTERGRAFT], or autograft. The other 3 groups consisted of the PEEK corpectomy devices filled 
with the same bone graft/substitute preparations. 
Autograft 
Locally harvested cancellous bone autograft from the excised vertebral body was implanted within and 
around the corpectomy device. 
rhBMP-2/CRM 
Around 2.5mL of 0.86 mg/mL rhBMP-2 solution was evenly distributed and allowed to soak into a 5-mL 
block of CRM [2.15mg total dose of rhBMP-2]. The CRM (MasterGraft Matrix; Medtronic) consists of 
97.5% biphasic calcium phosphate granules (15% HA/85%b-TCP) and 2.5% Type I bovine collagen by 
weight. 
rhBMP-2/ACS with MASTERGRAFT 
One 5.0 cm_2.5 cm_0.35 cm dry ACS and one 4.0 cm_2.5 cm_0.35 cm dry ACS were cut into 
approximately 40 small pieces. Around 2.5mL of 0.43 mg/mL rhBMP-2 solution was then evenly 
distributed onto the ACS pieces [1.08mg total dose of rhBMP-2]. After the prescribed 15-minute soak 
time, 2.5mL of Ceramic Granules (MASTERGRAFT Granules; Medtronic) were combined with the ACS 
pieces to create approximately 5mL of morselized mixture. This mixture was then packed into each type 
of corpectomy implant. A dose concentration of 0.43 mg/mL of rhBMP-2 on ACS has been used in 
several ovine interbody fusion studies.13,21 
Computerized Tomography 
At the 6-month postoperative time period, computed tomographic (CT) scans were performed on all 24 
specimens in 1.5mm slice widths. Sagittal and coronal reconstructions as well as axial scans were 
evaluated by an independent neuroradiologist, neurosurgeons, and orthopedic spine surgeons to 
determine the continuity of fusion mass and presence of bone. Criteria for fusion based on the CT scan 
was determined to be any continuous vertical column of bone from endplate to endplate. 
Table 1. Summary Table of CT Radiographic Results 
Group Treatment Samples Fusion Nonfusion 
1 PEEK Verte-Stack Cornerstone 
PSR+rhBMP-2/CRM 
4 4 0 
2 Pyramesh þ rhBMP-2/CRM 4 4 0 
3 PEEK Verte-Stack Cornerstone PSR 
þ rhBMP-2/ACS with 
MASTERGRAFT 
4 4 0 
4 Pyramesh þ rhBMP-2/ACS with 
MASTERGRAFT 
4 4 0 
5 PEEK Verte-Stack Cornerstone PSR 
þ autograft 
4 4 0 
6 Pyramesh þ autograft 4 2 2 
 
Undecalcified Histology and Microradiography 
After fixation was effected, tissue samples were rinsed in running tap water, sequentially dehydrated in 
graded alcohols, cleared in xylene, and infiltrated and embedded in graded catalyzed methyl  
ethacrylate. Undecalcified sections were cut in the sagittal plane continuously through the treated 
spines on diamond saws to an approximate thickness of 200 to 350mm. Differential staining using a 
trichrome stain was used to permit both histological and cytological differentiation. 
 In addition to stained undecalcified sections, microradiographs of 3 to 4 undecalcified sections 
from each treated level were produced. Microradiographs were ideal for differentiation of bone, 
ceramic granules, and the corpectomy devices because of radiodensity differences of these materials. 
The histological sections and microradiographs were evaluated concurrently for histologic fusion 
(continuous bony bridge from the cranial to the caudal vertebra) or the presence of pseudarthroses. The 
spinal levels were considered to be fused if greater than (>) 50% of the sections showed continuous 
bony bridging in any 1 region. A partial fusion existed if less than or equal to (_) 50% of the sections 
showed continuous bony bridging in any 1 region. A nonfusion existed if none of the sections showed 
continuous bony bridging. 
RESULTS 
Clinical 
The majority of the sheep underwent the surgical procedure and recovered without complications. 
Mean operative time ranged from 97 minutes for the PEEK Verte-Stack Cornerstone PSR and rhBMP-
2/CRMgroup to 154 minutes for the Pyramesh and rhBMP-2/CRM group. Differences in operative time 
were not statistically significant between individual treatment groups [P<0.13, analysis of variance 
(ANOVA)]; although when data were pooled by corpectomy device and examined, the mean operative 
time of 110 minutes for the PEEK corpectomy device groups was significantly less than the 130-minute 
mean operative time for the titanium mesh corpectomy device groups (P<0.047,one-tail t test). 
 Mean blood loss for the treatment groups ranged from 190 to 700mL with statistically 
significant differences for blood loss between treatment groups observed (P<0.01, ANOVA). The 
Pyramesh and autograft group had significantly more blood loss than the Pyramesh and rhBMP-2/CRM 
group and the Pyramesh and rhBMP-2/ACS with MASTERGRAFT group (both P<0.04, pairwise 
comparison, Student’s t). Similarly, the PEEK Verte-Stack Cornerstone PSR and autograft group had 
significantly more blood loss than the Pyramesh þ rhBMP-2/CRM group and the Pyramesh and rhBMP-
2/ACS with MASTERGRAFT group (both P<0.01, pairwise comparison, Student’s t). Finally, the PEEK 
Verte-Stack Cornerstone PSR and rhBMP-2/CRM group had significantly more blood loss than both the 
Pyramesh and rhBMP-2/CRM group as well as the Pyramesh and rhBMP-2/ACS with MASTERGRAFT 
group (both P<0.002, pairwise comparison, Student’s t). 
Radiographic 
Sagittal CT scan reconstructions (as seen in Figure 2) were used for the evaluation of fusion. CT 
radiographic results summarized by treatment group are presented in Table 1. All treated spines were 
determined to be fused with the exception of nonfusions in 2 of 4 spines in the Pyramesh and autograft 
group, resulting in a 50% radiographic fusion rate for that group. For rhBMP-2, 16 of 16 fusions occurred 
(100%), while in the autograft cohort, 6 of 8 (75%) fused (P¼0.038, Chi-squared test; P¼0.10, Fisher’s 
exact test). 
Histologic 
Histologic fusion results summarized by treatment group and presented in Table 2 compared favorably 
with CT radiographic fusion results as presented in Table 1. A subclinical infection was found in the peri-
implant histology of 1 of the sheep in the Pyramesh and autograft group (Group 6). Although the 
infection was not detected clinically, the infection most likely inhibited bone growth and subsequently 
obviated histologic fusion in this sheep. As such, this sheep was excluded from the group 6 fusion 
analysis in Table 2, so that for Group 6, (Pyramesh and autograft), N was reduced to 3. A representative 
stained, undecalcifed, histologic section and corresponding microradiograph, which shows a partial 
histologic fusion with bridging bone with incomplete bone fill inside the titanium corpectomy device 
filled with autograft (Group 6), is seen in Figure 3. Representative stained, undecalcifed, histologic 
sections and corresponding microradiographs, which show histologic fusion with bridging bone and 
complete de novo bone fill inside the titanium corpectomy devices filled with rhBMP-2/CRM (Group 2) 
as well as rhBMP-2/ACS with MASTERGRAFT (Group 4), are seen in Figures 4 and 5, respectively. 
Radiopaque incorporated ceramic granules are seen within the fusion masses in the corresponding 
microradiographs (Figures 4B and 5B) within the titanium mesh devices. In addition to bony bridging 
within the corpectomy devices, bony bridging was also seen ventral to both of the titanium mesh 
corpectomy devices in Figures 4 and 5. 
 Similar to the Pyramesh þ autograft group, 2 fusions, 1 partial histologic fusion and 1 nonfusion, 
were found in the PEEK Verte-Stack Cornerstone PSR and autograft group. A representative stained, 
undecalcifed, histologic section and corresponding microradiograph, which shows a histologic fusion 
with bridging bone with complete bone fill inside the PEEK corpectomy device filled with autograft 
(Group 5), is seen in Figure 6. Representative stained, undecalcifed, histologic sections and 
corresponding microradiographs, which show histologic fusion with bridging bone and complete de 
novo bone fill inside the PEEK corpectomy devices filled with rhBMP-2/CRM (Group 1) as well as rhBMP-
2/ACS with MASTERGRAFT (Group 3), are seen in Figures 7 and 8, respectively. Radiopaque incorporated 
ceramic granules were seen within the fusion masses in the corresponding microradiographs (Figures 7B 
and 8B) within the PEEK corpectomy devices. In addition, Figures 6B, 7B, and 8B show that the PEEK 
device is radiolucent. Bony bridging is observed ventral to all 3 of the PEEK corpectomy devices in 
Figures 6 through 8 in addition to bony bridging within the PEEK corpectomy devices. 
 Figure 2. (A) Sagittal reconstruction showing continuous bony bridging 
through a titanium corpectomy device implanted at 6 months in 
the sheep lumbar spine. (B) Sagittal reconstruction showing continuous 
bony bridging through a PEEK corpectomy device implanted at 
6 months in the sheep lumbar spine. 
 
Table 2. Summary Table of Histologic Fusion Results 
Group Treatment Samples (N) Histologic 
Fusion 
Partial Fusion Nonfusion 
1 PEEK Verte-Stack Cornerstone 
PSR þ 
rhBMP-2/CRM 
4 4 0 0 
2 Pyramesh þ rhBMP-2/CRM 4 4 0 0 
3 PEEK Verte-Stack Cornerstone 
PSR þ 
rhBMP-2/ACS with 
MASTERGRAFT 
4 3 1 0 
4 Pyramesh þ rhBMP-2/ACS with 
MASTERGRAFT 
4 2 2 0 
5 PEEK Verte-Stack Cornerstone 
PSR + autograft 
4 2 1 1 
6 Pyramesh + autograft 3* 2 1 0 
*Sheep #55 in Group 6 showed an infection. This most likely inhibited bone growth and subsequently obviated histologic 
fusion. As such, it has been excluded from the group fusion analysis, so that for Group 6, N¼3. 
Histology demonstrated de novo bone within a majority of the corpectomy devices, resulting in 
complete bone fill. Ceramic granules and autograft fragments were incorporated into fusion masses 
within the corpectomy device. Unincorporated autograft fragments and unincorporated ceramic 
granules were not observed. As summarized in Table 2, a few of the spines were rated as partial 
histologic fusions. In these spines, some histologic sections showed full fusion with complete bone fill. 
Other sections from the same spine showed thin (<1mm) ventral to dorsal bands of nonbony tissues 
obviating fusion. Despite the presence of these thin pseudarthroses, these sections also showed nearly 
complete bone fill within the rest of the corpectomy device. The resultant fusion rates for autograft and 
rhBMP-2 can be calculated by analyzing the histologic fusion data presented in Table 2 and combining 
‘‘fusion’’ and ‘‘partial fusion’’ results versus ‘‘nonfusion.’’ For rhBMP-2, 16 of 16 histologic fusions 
occurred (100%), while in the autograft cohort, 6 of 7 (85.7%) fused (P¼0.12, Chi-squared test; P¼0.30, 
Fisher’s exact test). 
 
Figure 3. Representative stained, undecalcifed, 
histologic section (A) and corresponding microradiograph 
(B) showing partial histologic fusion 
with bridging bone with incomplete bone fill 
inside the titanium corpectomy device filled with 
autograft (Group 6). No infection was present in 
peri-implant tissues. 
 
 
Figure 4. Representative stained, undecalcifed, 
histologic section (A) and corresponding microradiograph 
(B) showing histologic fusion with bridging 
bone and complete de novo bone fill inside 
the titanium corpectomy device filled with 
rhBMP-2/CRM (Group 2). Radiopaque incorporated 
ceramic granules are seen within the fusion 
mass in the corresponding microradiograph (B). In 
addition to bone within the corpectomy device, 
bony bridging is seen ventral to the device in 
both figures. 
 
 
Figure 5. Stained, undecalcifed, histologic section 
(A) and corresponding microradiograph (B) showing 
histologic fusion with bridging bone and 
complete de novo bone fill inside the titanium 
corpectomy device filled with rhBMP-2/ACS with 
MASTERGRAFT (Group 4). Radiopaque incorporated 
ceramic granules are seen within the fusion 
mass in the corresponding microradiograph (B). 
In addition to bone within the corpectomy 
device, bony bridging is seen ventral to the 
device in both figures. 
 
DISCUSSION 
On the basis of histology and CT scans, vertebral reconstruction with either formulation of rhBMP-2 
resulted in 100% fusion regardless of corpectomy device. There was continuous bone formation from 
endplate to endplate in all reconstructions using either formulation of rhBMP-2. Those vertebral defects 
undergoing reconstruction with autograft achieved only a 75% radiographic fusion rate. Although no 
animal model can fully predict human clinical results, 6 postoperative months appeared to 
 
Figure 6. Representative stained, undecalcifed, 
histologic section (A) and corresponding microradiograph 
(B) showing histologic fusion with 
bridging bone and complete bone fill inside the 
PEEK corpectomy device filled with autograft 
(Group 5). In addition to bone within the corpectomy 
device, bony bridging is seen ventral to the 
device in both figures. 
 
 
Figure 7. Representative stained, undecalcifed, 
histologic section (A) and corresponding microradiograph 
(B) showing histologic fusion with 
bridging bone and complete de novo bone fill 
inside the PEEK corpectomy device filled with 
rhBMP-2/CRM. Radiopaque incorporated ceramic 
granules are seen within the fusion mass in the 
corresponding microradiograph (B). In addition to 
bone within the corpectomy device, bony bridging 
is seen ventral to the device in both figures. 
 
provide valuable data on the ability of the instrumented corpectomy devices filled with bone graft and 
the bone graft substitutes to effect lumbar spinal fusion in the ovine model. In fact, both the PEEK and 
titanium corpectomy devices provided a sheltered environment for angiogenesis, the expression of the 
rhBMP-2 morphogen with the maintenance of a 3-D internal geometry, and the induction of a bony 
fusion mass with subsequent arthrodesis of the lumbar spinal level. 
 Thin pseudarthroses, observed by histology in some sections, would likely not be detectable by 
current radiographic methods, explaining the slight discrepancy between histologic fusion results and CT 
radiographic fusion results. One of the limitations of the current study is the fact that formal 
biomechanical testing was not conducted on the spines. Therefore, it is not known whether the thin 
pseudoarthroses detected by histology might be clinically relevant due to the biomechanical stability 
offered by the instrumented construct. 
 
Figure 8. Representative stained, undecalcifed, 
histologic section (A) and corresponding microradiograph 
(B) showing histologic fusion with 
bridging bone and complete de novo bone fill 
inside the PEEK corpectomy device filled with 
rhBMP-2/ACS with MASTERGRAFT (Group 3). 
Radiopaque incorporated ceramic granules are 
seen within the fusion mass in the corresponding 
microradiograph (B). 
Although differences in operative time were not statistically significant between individual 
treatment groups, data pooled by corpectomy device were statistically significant with the mean 
operative time for the PEEK corpectomy device groups being significantly less than the mean operative 
time for the titanium mesh corpectomy device groups. The titanium mesh devices took longer to 
prepare because of the requirement to cut the device in order to fit the vertebral defect. Thus, the 
modularity of the PEEK device with various sizes compared with the need to measure and cut the 
titanium mesh device is a possible reason for the observed statistically significant differences in mean 
operative time between corpectomy device groups. Differences in the mean operative time between 
treatment groups using bone autograft versus the synthetic bone graft substitutes were not statistically 
significant. With respect to blood loss, statistically significant differences for blood loss between 
treatment groups were observed in the current study with the Pyramesh and autograft group having 
significantly more blood loss than the Pyramesh and rhBMP-2/CRM group and the Pyramesh and 
rhBMP-2/ACS with MASTERGRAFT group. This finding is consistent with previous clinical literature that 
has documented decreased blood loss with the use of bone graft substitutes over bone autograft.22–25 
 With respect to efficacy, in the current study, vertebral reconstruction with either formulation 
of rhBMP-2 resulted in 100% fusion regardless of conduit. In the current study, adverse events including 
bone resorption and ectopic bone formation were not observed at 6 months. Obtaining enough 
bone graft material can be a challenge in spinal surgery. Although there are numerous biomaterials that 
are alternatives to or extenders of bone autograft in spine surgery, none are as efficacious as autograft. 
Autograft remains the gold standard for vertebral body reconstruction. Clinical outcomes for rhBMP-2 in 
spinal fusion have shown better clinical results than iliac crest bone while decreasing blood loss, 
operating time and costs while increasing patient satisfaction and fusion outcomes.26,27 To our 
knowledge, there have been no studies to date that show rhBMP-2 to be an acceptable alternative to 
autologous bone for reconstruction of a corpectomy. This study demonstrates that using rhBMP-2 may 
be a viable alternative to autologous bone graft in vertebral reconstruction, regardless of the conduit, 
especially when there is a limit to the amount of autogenous bone graft that can be harvested. 
Key Points 
Regardless of corpectomy device used, rhBMP-2/CRM or rhBMP-2/ACS with MASTERGRAFT resulted in a 
100% fusion rate compared with a 75% radiographic fusion rate in the autograft groups, indicating that 
both of the rhBMP-2 formulations have the potential to effect bony fusion and vertebral reconstruction 
within corpectomy devices. 
Both autograft fragments and ceramic granules were incorporated into the fusion masses with much of 
the ceramic granules being resorbed by 6 months. 
PEEK corpectomy devices were radiolucent, which could allow for an easier determination of 
radiographic fusion than the radiopaque titanium mesh devices. 
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